Immunomedics (IMMU) & Its Peers Head to Head Review
Immunomedics (NASDAQ: IMMU) is one of 188 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Immunomedics to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations.
Institutional & Insider Ownership
76.3% of Immunomedics shares are owned by institutional investors. Comparatively, 48.0% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 6.6% of Immunomedics shares are owned by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This is a breakdown of current ratings and target prices for Immunomedics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Immunomedics presently has a consensus price target of $15.50, suggesting a potential upside of 24.60%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.22%. Given Immunomedics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Immunomedics is more favorable than its rivals.
This table compares Immunomedics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Immunomedics and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Immunomedics||$3.09 million||-$153.20 million||-5.58|
|Immunomedics Competitors||$217.29 million||-$39.39 million||-66.95|
Immunomedics’ rivals have higher revenue and earnings than Immunomedics. Immunomedics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Immunomedics has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Immunomedics’ rivals have a beta of 1.56, indicating that their average share price is 56% more volatile than the S&P 500.
Immunomedics rivals beat Immunomedics on 7 of the 12 factors compared.
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.
Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.